• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

野生型转甲状腺素蛋白淀粉样心肌病疾病阶段的运动血液动力学和线粒体氧化能力。

Exercise Hemodynamics and Mitochondrial Oxidative Capacity in Disease Stages of Wild-Type Transthyretin Amyloid Cardiomyopathy.

机构信息

Department of Cardiology Aarhus University Hospital Aarhus Denmark.

The National Amyloidosis Centre, The Royal Free Hospital London UK.

出版信息

J Am Heart Assoc. 2024 Jul 2;13(13):e034213. doi: 10.1161/JAHA.124.034213. Epub 2024 Jun 27.

DOI:10.1161/JAHA.124.034213
PMID:38934860
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11255680/
Abstract

BACKGROUND

Wild-type transthyretin amyloid (ATTRwt) cardiomyopathy is increasingly recognized in the development of heart failure. The link between cardiac performance, hemodynamics, and mitochondrial function in disease stages of ATTRwt has not previously been studied but may provide new insights into the pathophysiology and clinical performance of the patients.

METHODS AND RESULTS

The study investigated 47 patients diagnosed with ATTRwt at Aarhus University Hospital, Denmark. Patients were stratified according to the disease stages of the National Amyloidosis Centre (NAC) as NAC I with low levels of NT-proBNP (N-terminal pro-B-type natriuretic peptide) (NAC I-L, n=14), NAC I with high levels NT-proBNP (NAC I-H, n=20), and NAC II-III (n=13). Exercise testing with simultaneous right heart catheterization was performed in all patients. Endomyocardial biopsies were collected from the patients and the mitochondrial oxidative phosphorylation capacity was assessed. All NAC disease groups, even in the NAC I-L group, a significant abnormal increase in biventricular filling pressures were noted during exercise while the filling pressures was normal or near normal at rest. The inotropic response to exercise was reduced with diminished increase in cardiac output which was significantly more pronounced in the NAC I-H (Diff. -2.4, 95% CI (-4.2: -0.7), =0.00) and the NAC II-III group (Diff: -3.1 L/min, 95% CI (-5.2: -1.1), =0.00) compared with the NAC I-L group. The pulmonary artery wedge pressure to cardiac output ratio at peak exercise was significantly different between NAC I-L and NAC II-III (Diff: 1.6 mm Hg*min/L, 95% CI (0.01:3.3, =0.04)). Patients with ATTRwt had a reduced oxidative phosphorylation capacity which correlated to left ventricular mass but not to cardiac output capacity.

CONCLUSIONS

An abnormal restrictive left ventricle and right ventricle response to exercise was demonstrated, even present in patients with early-stage ATTRwt. In more advanced disease stages a progressive impairment of the pressure-flow relationship was noted. The myocyte energetics is deranged but not associated to the contractile reserve or restrictive filling characteristics in ATTRwt.

摘要

背景

野生型转甲状腺素蛋白淀粉样变(ATTRwt)心肌病在心力衰竭的发展中日益受到关注。在 ATTRwt 的疾病阶段,心脏功能、血液动力学和线粒体功能之间的联系以前尚未研究过,但可能为患者的病理生理学和临床表现提供新的见解。

方法和结果

该研究调查了丹麦奥胡斯大学医院诊断为 ATTRwt 的 47 名患者。根据国家淀粉样变性中心(NAC)的疾病阶段,患者分为 NAC I 低 NT-proBNP(N 端脑利钠肽前体)水平(NAC I-L,n=14)、NAC I 高 NT-proBNP(NAC I-H,n=20)和 NAC II-III(n=13)。所有患者均进行运动试验并同时进行右心导管检查。从患者中采集心肌活检,并评估线粒体氧化磷酸化能力。所有 NAC 疾病组,甚至在 NAC I-L 组,在运动过程中均观察到左右心室充盈压显著异常增加,而在休息时充盈压正常或接近正常。运动时的变力反应降低,心输出量增加减少,在 NAC I-H(差异-2.4,95%CI(-4.2:-0.7),=0.00)和 NAC II-III 组(差异:-3.1 L/min,95%CI(-5.2:-1.1),=0.00)中更为明显与 NAC I-L 组相比。运动峰值时肺动脉楔压与心输出量比值在 NAC I-L 与 NAC II-III 之间有显著差异(差异:1.6mmHg*min/L,95%CI(0.01:3.3),=0.04)。ATTRwt 患者的氧化磷酸化能力降低,与左心室质量相关,但与心输出量能力无关。

结论

即使在早期 ATTRwt 患者中,也发现了异常的限制性左心室和右心室对运动的反应。在更晚期的疾病阶段,压力-流量关系逐渐受损。ATTRwt 患者的肌细胞能量代谢紊乱,但与收缩储备或限制性充盈特征无关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3db/11255680/9e7c53536273/JAH3-13-e034213-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3db/11255680/15caba81d7ca/JAH3-13-e034213-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3db/11255680/4d73228698a0/JAH3-13-e034213-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3db/11255680/9e7c53536273/JAH3-13-e034213-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3db/11255680/15caba81d7ca/JAH3-13-e034213-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3db/11255680/4d73228698a0/JAH3-13-e034213-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3db/11255680/9e7c53536273/JAH3-13-e034213-g002.jpg

相似文献

1
Exercise Hemodynamics and Mitochondrial Oxidative Capacity in Disease Stages of Wild-Type Transthyretin Amyloid Cardiomyopathy.野生型转甲状腺素蛋白淀粉样心肌病疾病阶段的运动血液动力学和线粒体氧化能力。
J Am Heart Assoc. 2024 Jul 2;13(13):e034213. doi: 10.1161/JAHA.124.034213. Epub 2024 Jun 27.
2
Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study.野生型转甲状腺素蛋白心脏淀粉样变在老年人群中并不罕见:CATCH 筛查研究。
Eur J Prev Cardiol. 2024 Aug 22;31(11):1410-1417. doi: 10.1093/eurjpc/zwae093.
3
Inotropic myocardial reserve deficiency is the predominant feature of exercise haemodynamics in cardiac amyloidosis.收缩性心肌储备缺陷是心脏淀粉样变运动血液动力学的主要特征。
Eur J Heart Fail. 2017 Nov;19(11):1457-1465. doi: 10.1002/ejhf.899. Epub 2017 Aug 24.
4
Changes of clinical characteristics, distribution of red flags and prognosis in contemporary patients with wild-type transthyretin amyloidosis cardiomyopathy.当代野生型转甲状腺素蛋白淀粉样变性心肌病患者的临床特征变化、红色信号分布和预后。
Ann Med. 2024 Dec;56(1):2398735. doi: 10.1080/07853890.2024.2398735. Epub 2024 Sep 9.
5
Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.Patisiran,一种 RNA 干扰疗法,对遗传性转甲状腺素蛋白介导的淀粉样变性患者心脏参数的影响。
Circulation. 2019 Jan 22;139(4):431-443. doi: 10.1161/CIRCULATIONAHA.118.035831.
6
Transthyretin amyloid cardiomyopathy among patients with heart failure and preserved ejection fraction: the AMY score.心力衰竭伴射血分数保留患者中的转甲状腺素蛋白淀粉样变心肌病:AMY 评分。
ESC Heart Fail. 2024 Aug;11(4):2172-2181. doi: 10.1002/ehf2.14786. Epub 2024 Apr 13.
7
Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.转甲状腺素相关与轻链心脏淀粉样变性的左心室结构和功能。
Circulation. 2014 May 6;129(18):1840-9. doi: 10.1161/CIRCULATIONAHA.113.006242. Epub 2014 Feb 21.
8
Deep phenotyping of p.(V142I)-associated variant transthyretin amyloid cardiomyopathy: Distinct from wild-type transthyretin amyloidosis?V142I 相关变异转甲状腺素蛋白淀粉样心肌病的深度表型分析:与野生型转甲状腺素蛋白淀粉样变性不同?
Eur J Heart Fail. 2024 Feb;26(2):383-393. doi: 10.1002/ejhf.3088. Epub 2024 Jan 28.
9
Outcomes After Cardiac Transplant for Wild Type Transthyretin Amyloidosis.野生型转甲状腺素蛋白淀粉样变性心脏移植后的结局。
Transplantation. 2018 Nov;102(11):1909-1913. doi: 10.1097/TP.0000000000002240.
10
Assessment of transthyretin instability in patients with wild-type transthyretin amyloid cardiomyopathy.评估野生型转甲状腺素蛋白淀粉样心肌病患者的转甲状腺素蛋白不稳定性。
Sci Rep. 2024 Sep 3;14(1):20508. doi: 10.1038/s41598-024-71446-8.

引用本文的文献

1
Left ventricular outflow tract obstruction in transthyretin amyloid cardiomyopathy: a case report on diagnostic and treatment challenges and role of alcohol septal ablation.转甲状腺素蛋白淀粉样变心肌病中的左心室流出道梗阻:一例关于诊断、治疗挑战及酒精间隔消融作用的病例报告
Eur Heart J Case Rep. 2025 May 12;9(5):ytaf233. doi: 10.1093/ehjcr/ytaf233. eCollection 2025 May.

本文引用的文献

1
Association of Right Ventricular Myocardial Blood Flow With Pulmonary Pressures and Outcome in Cardiac Amyloidosis.右心室心肌血流与心脏淀粉样变患者肺动脉压和预后的相关性。
JACC Cardiovasc Imaging. 2023 Sep;16(9):1193-1204. doi: 10.1016/j.jcmg.2023.01.024. Epub 2023 Apr 12.
2
Health-related quality of life among transthyretin amyloid cardiomyopathy patients.转甲状腺素蛋白淀粉样变心肌病患者的健康相关生活质量。
ESC Heart Fail. 2023 Jun;10(3):1871-1882. doi: 10.1002/ehf2.14350. Epub 2023 Mar 22.
3
Decongestion With Acetazolamide in Acute Decompensated Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Prespecified Analysis From the ADVOR Trial.
在不同左心室射血分数范围内使用乙酰唑胺治疗急性失代偿性心力衰竭的减充血作用:ADVOR试验的一项预先设定分析
Circulation. 2023 Jan 17;147(3):201-211. doi: 10.1161/CIRCULATIONAHA.122.062486. Epub 2022 Nov 6.
4
Incidence and predictors of worsening heart failure in patients with wild-type transthyretin cardiac amyloidosis.野生型转甲状腺素蛋白心脏淀粉样变患者心力衰竭恶化的发生率和预测因素。
ESC Heart Fail. 2022 Oct;9(5):2978-2987. doi: 10.1002/ehf2.14000. Epub 2022 Jun 22.
5
Characteristics and natural history of early-stage cardiac transthyretin amyloidosis.早期心脏转甲状腺素蛋白淀粉样变性的特征与自然病史。
Eur Heart J. 2022 Jul 14;43(27):2622-2632. doi: 10.1093/eurheartj/ehac259.
6
Abnormal mitochondrial function and morphology in heart transplanted patients with cardiac allograft vasculopathy.心脏移植患者心脏同种异体血管病中线粒体功能和形态异常。
J Heart Lung Transplant. 2022 Jun;41(6):732-741. doi: 10.1016/j.healun.2022.01.1376. Epub 2022 Feb 3.
7
ATTR Amyloidosis: Current and Emerging Management Strategies: State-of-the-Art Review.转甲状腺素蛋白淀粉样变性:当前及新出现的管理策略:最新综述
JACC CardioOncol. 2021 Oct 19;3(4):488-505. doi: 10.1016/j.jaccao.2021.06.006. eCollection 2021 Oct.
8
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases.心脏淀粉样变性的诊断与治疗:欧洲心脏病学会心肌与心包疾病工作组的立场声明
Eur Heart J. 2021 Apr 21;42(16):1554-1568. doi: 10.1093/eurheartj/ehab072.
9
Prognostic implications of left ventricular myocardial work indices in cardiac amyloidosis.左心室心肌做功指数在心淀粉样变中的预后意义。
Eur Heart J Cardiovasc Imaging. 2021 May 10;22(6):695-704. doi: 10.1093/ehjci/jeaa097.
10
Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis.心脏转甲状腺素蛋白淀粉样变性的自然病史、生活质量和结局。
Circulation. 2019 Jul 2;140(1):16-26. doi: 10.1161/CIRCULATIONAHA.118.038169. Epub 2019 May 21.